Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYCS pseudogene 38 (CYCSP38), also referred to as HCP38 or HC2, is a non-functional, processed pseudogene sequence in the human genome originating from the CYCS (cytochrome c, somatic) gene[1][4][7]. Unlike the parent gene CYCS, which encodes an essential mitochondrial heme protein involved in the electron transport chain and apoptosis, CYCSP38 is not transcribed into RNA or translated into a protein, and it exhibits disablements such as frame shifts, truncations, or insertions that prevent normal expression[1][4][8]. CYCSP38 is one of a family of more than 40 cytochrome c pseudogenes dispersed throughout the genome and serves no documented functional role in cellular physiology or disease. It is not considered a therapeutic target for drug development and is not implicated in human disease or used as a biomarker[4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CYCS pseudogene 38 (CYCSP38).